An observational study in Rare Diseases and Genetic Predisposition to Disease, sponsored by University Hospital Tuebingen. Recruiting at 1 site in Germany. Per ClinicalTrials.gov, last updated 2025-03-30.
Sponsored by University Hospital Tuebingen · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
In the DISCO-TWIN study (prospective, open-label molecular-genetic study), twin pairs with one healthy and one affected twin with molecularly undiagnosed diseases will be analysed by means of omics technologies and/ or re-analysed using existing datasets. Phenotype and omics data will be shared within the University Hospital Tübingen and with external collaborators to improve the diagnostic rate of the subjects included in the study.
592 studies on the registry are indexed under Rare Diseases; 125 are open to participants now.
This study's planned enrollment of 50 is below the median of 133 across 208 observational studies indexed under Rare Diseases.
Browse Rare Diseases studies →University Hospital Tuebingen is the lead sponsor of 492 studies on the registry; 110 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Twin pair monozygotic clinically (phenotypic) discordant twins
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Genetic: NGS Diagnostic
Twin with unclear rare diseases, clinically characterized in the context of outpatient/ inpatient standard care at the University Hospital Tübingen (UKT) or cooperating location.
Genetic: NGS Diagnostic
Blood take for genetic diagnostic.
Also known as: Omics Technology
Number of new Candidate Genes
Number of new Candidate Genes for complex or serious diseases through a comparative genetic analysis of monozygotic clinically discordant twins
Time frame: Day 1
Number of putative disease causes
Number characterizations of the identified putative disease causes.
Time frame: Day 1
Number of diagnosis
Number of patients receiving appropriate therapy after successful diagnosis
Time frame: Day 1
Number of molecular causes of diagnostically unclear rare diseases
Number of molecular causes of diagnostically unclear rare diseases
Time frame: Day 1
Plan to share: No
No publications or documents are linked to this record.
Started Dec 2019 (actual). Primary completion is estimated for Dec 2025, 72 months after the start.
Of 88 observational studies under Rare Diseases, half reached primary completion within 118 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 183. This study's planned 72 months is below that.
Rare Diseases covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital Tuebingen →